Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 70

Sort by

Sort Order Select

Journal Articles

Association between Smoking Intensity, Genetic Mutations, and Disease Progression in Myelodysplastic Syndromes

Blood (2024) 144 (Supplement 1): 4597.

https://doi.org/10.1182/blood-2024-206034

Published: 2024

Journal Articles

Progression of Myelodysplastic Syndromes in the MDS Natural History Study (MDS NHS)

Blood (2024) 144 (Supplement 1): 1831.

https://doi.org/10.1182/blood-2024-201613

Published: 2024

Journal Articles

Impact of Social Determinants of Health on Overall Survival in Patients with AML By European Leukemianet Risk Group

Shai O. Shimony, Yating Wang, Angel Cronin, Thomas P Walsh, Anne Charles, Natalie Slopen, Maximilian Stahl, Rebecca P. Bystrom, Marlise R. Luskin, Gregory Abel, Daniel J. DeAngelo, Richard M Stone, R. Coleman Lindsley, Andrew Hantel

Blood (2024) 144 (Supplement 1): 5171.

https://doi.org/10.1182/blood-2024-203644

Published: 2024

Journal Articles

AML-MR Mutations Drive the Benefit of CPX-351 over 7+3 in the Pivotal Phase 3 AML Trial

Shai O. Shimony, Heardley Murdock, Julia Keating, Christopher R. Reilly, Harrison K. Tsai, Christopher J. Gibson, Stefan Faderl, Tony Wagner, Nalina Dronamraju, Tara L. Lin, Ellen K. Ritchie, Thomas Prebet, Jorge E. Cortes, Geoffrey L. Uy, Jeffrey E Lancet, Donna S. Neuberg, Richard M. Stone, R. Coleman Lindsley

Blood (2024) 144 (Supplement 1): 60.

https://doi.org/10.1182/blood-2024-200413

Published: 2024

Journal Articles

Robust Copy Number Alteration Detection (RCNA): A Novel Algorithm for Detecting Copy-Number Alterations for Targeted Gene Sequencing Experiments

Travis L Jensen, Matthew D Bradley, Ling Zhang, Rafael Bejar, R. Coleman Lindsley, Matthew J. Walter, Johannes Goll

Blood (2024) 144 (Supplement 1): 3220.

https://doi.org/10.1182/blood-2024-210552

Published: 2024

Journal Articles

CRISPR-based rapid molecular diagnostic tests for fusion-driven leukemias

Rahul S. Vedula, Hannah Q. Karp, Jeremy Koob, Felicia Lim, Jacqueline S. Garcia, Eric S. Winer, Marlise R. Luskin, Gabriel Ghiaur, Annette S. Kim, Lan W. Beppu, Olga Sala-Torra, Jerald Radich, Jonathan Gootenberg, Omar Abudayyeh, Feng Zhang, R. Coleman Lindsley

Blood (2024) 144 (12): 1290–1299.

https://doi.org/10.1182/blood.2023022908

Published: 2024

Includes: Supplemental data

Journal Articles

PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy

Blood (2023) 142 (24): 2079–2091.

https://doi.org/10.1182/blood.2023020331

Published: 2023

Includes: Supplemental data

Journal Articles

Intensive Induction Chemotherapy Vs Hypomethylating Agents + Venetoclax (HMA/VEN) in NPM1 -Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study

Jan Philipp Bewersdorf, Shai Shimony, Rory M. Shallis, Yiwen Liu, Eva Johanna Schaefer, Amer M. Zeidan, Aaron D. Goldberg, Eytan M. Stein, Guido Marcucci, R. Coleman Lindsley, Evan C. Chen, Jorge Ramos, Anthony Selwyn Stein, Daniel J. DeAngelo, Donna S. Neuberg, Richard M Stone, Brian J. Ball, Maximilian Stahl

Blood (2023) 142 (Supplement 1): 2964.

https://doi.org/10.1182/blood-2023-174285

Published: 2023

Journal Articles

Unlike TET2 and ASXL1 , Co-Occurring DNMT3A Mutations Are Not Associated with Increased Age in JAK2 -Mutant Myeloproliferative Neoplasms (MPNs)

Joan How, Anna E. Marneth, Baransel Kamaz, Chulwoo J. Kim, Donna S. Neuberg, Siyang Ren, Mohammed Wazir, Lachelle D. Weeks, Maximilian Stahl, Daniel J. DeAngelo, R. Coleman Lindsley, Marlise R. Luskin, Sahand Hormoz, Ann Mullally

Blood (2023) 142 (Supplement 1): 4521.

https://doi.org/10.1182/blood-2023-179407

Published: 2023

Journal Articles

Impact of Clinical and Genetic Factors on Myelofibrosis Outcomes after Allogeneic Transplantation

Mahasweta Gooptu, Haesook T. Kim, Kaina Chen, Ann Mullally, Joseph Antin, Corey Cutler, Amar H Kelkar, John Koreth, Roman M. Shapiro, Robert J. Soiffer, Daniel J. DeAngelo, Jacqueline S. Garcia, Marlise R. Luskin, Richard M Stone, Martha Wadleigh, Eric S. Winer, R. Coleman Lindsley, Vincent Ho

Blood (2023) 142 (Supplement 1): 4978.

https://doi.org/10.1182/blood-2023-178684

Published: 2023

Journal Articles

Intensive Induction Chemotherapy (IC) Vs Hypomethylating Agents + Venetoclax (HMA/VEN) in IDH1- or IDH2 -Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study

Blood (2023) 142 (Supplement 1): 1589.

https://doi.org/10.1182/blood-2023-174283

Published: 2023

Journal Articles

Molecular Ontogeny in AML Is Both Prognostic and Predictive in Patients Treated with Hypomethylating Agents Plus Venetoclax

Shai Shimony, Jacqueline S. Garcia, Julia Keating, Evan C. Chen, Marlise R. Luskin, Maximilian Stahl, Donna S. Neuberg, Daniel J. DeAngelo, Richard M Stone, R. Coleman Lindsley

Blood (2023) 142 (Supplement 1): 977.

https://doi.org/10.1182/blood-2023-173935

Published: 2023

Journal Articles

What Is the Optimal Treatment Modality in Molecularly Defined Secondary AML? a Multicenter Cohort Study

Shai Shimony, Jan Philipp Bewersdorf, Rory M. Shallis, Yiwen Liu, Eva Johanna Schaefer, Amer M. Zeidan, Aaron D. Goldberg, Eytan M. Stein, Guido Marcucci, Evan C. Chen, Jorge Ramos, R. Coleman Lindsley, Anthony Selwyn Stein, Daniel J. DeAngelo, Donna S. Neuberg, Richard M Stone, Brian J. Ball, Maximilian Stahl

Blood (2023) 142 (Supplement 1): 1478.

https://doi.org/10.1182/blood-2023-172763

Published: 2023

Journal Articles

Cardiovascular Risk Factors Are Common in Myeloproliferative Neoplasms and Portend Worse Survival and Thrombotic Outcomes

Joan How, Orly Leiva, Anna E. Marneth, Baransel Kamaz, Chulwoo J. Kim, Lachelle D. Weeks, Mohammed Wazir, Maximilian Stahl, Daniel J. DeAngelo, R. Coleman Lindsley, Marlise R. Luskin, Gabriela S. Hobbs

Blood (2023) 142 (Supplement 1): 4568.

https://doi.org/10.1182/blood-2023-179324

Published: 2023

Journal Articles

Germ line predisposition variants occur in myelodysplastic syndrome patients of all ages

Blood (2022) 140 (24): 2533–2548.

https://doi.org/10.1182/blood.2022015790

Published: 2022

Includes: Supplemental data

Journal Articles

Mutant Srsf2 Diminishes Jak2 V617F -Induced Erythrocytosis in Mice and Is Associated with Lower Hemoglobin in Patients with Chronic Phase JAK2 -Mutant MPN

Anna E Marneth, Jonas S. Jutzi, Chulwoo J. Kim, Charles Laurore, Anastasia Tishena, Frederike Kramer, Azucena V. Rocha, Mohammed Wazir, Lachelle D. Weeks, Joan How, Maximilian F. Stahl, Marlise R. Luskin, R. Coleman Lindsley, Olga Pozdnyakova, Timothy A. Graubert, Ann Mullally

Blood (2022) 140 (Supplement 1): 1089–1090.

https://doi.org/10.1182/blood-2022-158823

Published: 2022

Journal Articles

Targeting a Putative Intronic Splicing Silencer Salvages Expression from the Recurrent SBDS C.258+2T>C Mutant Allele in Shwachman-Diamond Syndrome Patient Cells and Mouse Model

Blood (2022) 140 (Supplement 1): 2944–2945.

https://doi.org/10.1182/blood-2022-169379

Published: 2022

Journal Articles

Prediction of Risk for Myeloid Malignancy in Clonal Hematopoiesis

Lachelle D. Weeks, Abhishek Niroula, Donna S. Neuberg, Waihay J. Wong, R. Coleman Lindsley, Marlise R. Luskin, Nancy Berliner, Richard M. Stone, Daniel J DeAngelo, Robert J Soiffer, Md Mesbah Uddin, Christopher J. Gibson, Alexander G. Bick, Gabriel K. Griffin, Siddhartha Jaiswal, Luca Malcovati, Pradeep Natarajan, Benjamin L. Ebert

Blood (2022) 140 (Supplement 1): 2229–2231.

https://doi.org/10.1182/blood-2022-158960

Published: 2022

Journal Articles

Umbrella Trial in Myeloid Malignancies: The Myelomatch National Clinical Trials Network Precision Medicine Initiative

Blood (2022) 140 (Supplement 1): 9057–9060.

https://doi.org/10.1182/blood-2022-169307

Published: 2022

Journal Articles

FLT3-ITD Does Not Predict Inferior Prognosis Compared with FLT3- wild Type in Acute Myeloid Leukemia (AML) Patients Age ≥ 60 Years: A Retrospective Cohort Study

Shai Shimony, Geoffrey G Fell, Evan C. Chen, Harrison Tsai, Martha Wadleigh, Eric S. Winer, Jacqueline S. Garcia, Marlise R. Luskin, Maximilian F. Stahl, Donna S. Neuberg, Daniel J DeAngelo, R. Coleman Lindsley, Richard M. Stone

Blood (2022) 140 (Supplement 1): 8938–8939.

https://doi.org/10.1182/blood-2022-162716

Published: 2022

NARROW

Association between Smoking Intensity, Genetic Mutations, and Disease Progression in Myelodysplastic Syndromes

Progression of Myelodysplastic Syndromes in the MDS Natural History Study (MDS NHS)

Impact of Social Determinants of Health on Overall Survival in Patients with AML By European Leukemianet Risk Group

AML-MR Mutations Drive the Benefit of CPX-351 over 7+3 in the Pivotal Phase 3 AML Trial

Robust Copy Number Alteration Detection (RCNA): A Novel Algorithm for Detecting Copy-Number Alterations for Targeted Gene Sequencing Experiments

CRISPR-based rapid molecular diagnostic tests for fusion-driven leukemias

PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy

Intensive Induction Chemotherapy Vs Hypomethylating Agents + Venetoclax (HMA/VEN) in NPM1 -Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study

Unlike TET2 and ASXL1 , Co-Occurring DNMT3A Mutations Are Not Associated with Increased Age in JAK2 -Mutant Myeloproliferative Neoplasms (MPNs)

Impact of Clinical and Genetic Factors on Myelofibrosis Outcomes after Allogeneic Transplantation

Intensive Induction Chemotherapy (IC) Vs Hypomethylating Agents + Venetoclax (HMA/VEN) in IDH1- or IDH2 -Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study

Molecular Ontogeny in AML Is Both Prognostic and Predictive in Patients Treated with Hypomethylating Agents Plus Venetoclax

What Is the Optimal Treatment Modality in Molecularly Defined Secondary AML? a Multicenter Cohort Study

Cardiovascular Risk Factors Are Common in Myeloproliferative Neoplasms and Portend Worse Survival and Thrombotic Outcomes

Germ line predisposition variants occur in myelodysplastic syndrome patients of all ages

Mutant Srsf2 Diminishes Jak2 V617F -Induced Erythrocytosis in Mice and Is Associated with Lower Hemoglobin in Patients with Chronic Phase JAK2 -Mutant MPN

Targeting a Putative Intronic Splicing Silencer Salvages Expression from the Recurrent SBDS C.258+2T>C Mutant Allele in Shwachman-Diamond Syndrome Patient Cells and Mouse Model

Prediction of Risk for Myeloid Malignancy in Clonal Hematopoiesis

Umbrella Trial in Myeloid Malignancies: The Myelomatch National Clinical Trials Network Precision Medicine Initiative

FLT3-ITD Does Not Predict Inferior Prognosis Compared with FLT3- wild Type in Acute Myeloid Leukemia (AML) Patients Age ≥ 60 Years: A Retrospective Cohort Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only